Twist Bioscience Co. (NASDAQ:TWST) COO Sells $65,480.88 in Stock

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) COO Patrick John Finn sold 2,174 shares of the firm's stock in a transaction dated Tuesday, April 23rd. The shares were sold at an average price of $30.12, for a total value of $65,480.88. Following the sale, the chief operating officer now owns 176,206 shares in the company, valued at $5,307,324.72. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Patrick John Finn also recently made the following trade(s):

• On Tuesday, April 2nd, Patrick John Finn sold 492 shares of Twist Bioscience stock. The stock was sold at an average price of $32.74, for a total value of $16,108.08.

Twist Bioscience Price Performance

NASDAQ:TWST traded up $0.33 during midday trading on Thursday, reaching $31.08. 1,234,627 shares of the company traded hands, compared to its average volume of 931,222. Twist Bioscience Co. has a twelve month low of $11.46 and a twelve month high of $43.21. The company has a fifty day moving average price of $34.97 and a 200 day moving average price of $30.32. The firm has a market capitalization of $1.80 billion, a price-to-earnings ratio of -8.61 and a beta of 1.62.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its quarterly earnings results on Friday, February 2nd. The company reported ($0.75) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.78) by $0.03. Twist Bioscience had a negative return on equity of 32.16% and a negative net margin of 78.44%. The company had revenue of $71.50 million during the quarter, compared to analyst estimates of $67.59 million. During the same quarter in the previous year, the firm posted ($0.74) EPS. The firm's quarterly revenue was up 31.8% on a year-over-year basis. On average, equities research analysts forecast that Twist Bioscience Co. will post -3.17 earnings per share for the current fiscal year.

Institutional Trading of Twist Bioscience

A number of hedge funds and other institutional investors have recently modified their holdings of TWST. Federated Hermes Inc. bought a new stake in shares of Twist Bioscience in the 3rd quarter worth $29,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Twist Bioscience by 96.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,470 shares of the company's stock worth $30,000 after buying an additional 721 shares in the last quarter. EdgeRock Capital LLC bought a new stake in shares of Twist Bioscience in the 4th quarter worth $30,000. Allspring Global Investments Holdings LLC raised its stake in shares of Twist Bioscience by 51.8% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 3,453 shares of the company's stock worth $70,000 after buying an additional 1,179 shares in the last quarter. Finally, International Assets Investment Management LLC raised its stake in shares of Twist Bioscience by 3,519.8% in the 4th quarter. International Assets Investment Management LLC now owns 4,018 shares of the company's stock worth $148,000 after buying an additional 3,907 shares in the last quarter.

Wall Street Analysts Forecast Growth

TWST has been the topic of several analyst reports. Barclays dropped their price objective on Twist Bioscience from $45.00 to $40.00 and set an "overweight" rating on the stock in a report on Wednesday, April 10th. Scotiabank lifted their target price on Twist Bioscience from $30.00 to $43.00 and gave the stock a "sector outperform" rating in a research report on Monday, February 5th. Finally, The Goldman Sachs Group upgraded Twist Bioscience from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $25.00 to $45.00 in a research report on Wednesday, January 17th.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.